US Regulatory Roundup, December 2018: A Guilty Plea, And A Changing Regulatory Landscape
Executive Summary
The closing months of 2018 have turned out to be a dynamic period for the US medtech regulatory community. Journalists turned significant scrutiny toward FDA's oversight of the sector, even as the agency moved full steam ahead with important policy reforms. These issues are reflected in Medtech Insight's most popular US regulatory and policy articles in December.
You may also be interested in...
FDA Eyes Upclassification, Labeling Guidance To Address Stapler Risks
The US agency sent a letter to health-care providers spotlighting its analysis of the increasing numbers of adverse events linked to surgical staplers and implantable staples, and its plans for a draft guidance on labeling and an advisory panel meeting to consider a 510(k) requirement for the products.
Device Week, March 8, 2019 – Scott Gottlieb Resigns
On the latest Medtech Insight podcast, David Filmore and Ferdous Al-Faruque discuss the unexpected news that Scott Gottlieb is leaving US FDA next month. What has been his legacy for medtech, and who will replace him?
Scott Gottlieb Calls It Quits After An Active Tenure At US FDA
The commissioner says he will step down next month, leaving a legacy of active policy development, but also a lot of initiatives and pilot projects that are in the middle of being implemented.